ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab (NCT07320326) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
China159 participantsStarted 2025-12-30
Plain-language summary
This registry study will provide valuable evidence to assess and validate its effectiveness in the Chinese MM population, refine clinical application strategies, and support the optimization of BCMA BsAbs use in MM treatment in China.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female patients above 18 years old
✓. Patients diagnosed with RRMM(IMWG)
✓. Prior lines of therapy must include a proteasome inhibitor, an immunomodulatory drug and anti-CD38 monoclonal antibody in any order during the course of treatment
✓. Patients received at least 1 treatment dose of Elranatamab treatment after commercial launch in China and according to the approved product label (routine-care) in China (consistent with the approved label in China)\*
✓. Patients understand and voluntarily sign an ICF .
✓. Male or female patients above 18 years old
✓. Patients diagnosed with RRMM (IMWG)
✓. Prior lines of therapy must include a proteasome inhibitor, an immunomodulatory drug and anti-CD38 monoclonal antibody in any order during the course of treatment
Exclusion criteria
✕. Patients with documented diagnosis of other cancers prior to the diagnosis of MM
✕. Patients enrolled in interventional clinical trials of any drug for MM treatment
✕. Patients with incomplete medical records or missing clinical laboratory data that preclude effectiveness evaluation.
✕. Patients who, in the opinion of the investigator, have other factors that make them unsuitable for study participation.
What they're measuring
1
ORR
Timeframe: At the time from the date of first dose until the first documentation of PD, death or start of new anticancer therapy, whichever occurs first , assessed up to 27 months.